<DOC>
	<DOCNO>NCT00271323</DOCNO>
	<brief_summary>- Primary : To determine safety profile treatment group . - Secondary : To determine efficacy term overall response , disease free survival survival 1 2 year .</brief_summary>
	<brief_title>Safety Study Docetaxel/Cisplatin Induction Therapy Followed Concurrent Chemoradiotherapy Concurrent Chemoradiotherapy Followed Consolidation Docetaxel/Cisplatin NSCLC Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Informed consent form obtain , sign date specific protocol procedure . 2 . Histologically cytologically confirm NSCLC ( adenocarcinoma , squamous cell carcinoma , large cell carcinoma combination ) 3 . Patients must loco regionally advanced unresectable NSCLC ; Stage IIIA clinical multiple N2 node ( preferably histological cytological confirmation ) . Patients peripheral tumour low lobe contralateral upper mediastinal node station N2 excludedÂ· Stage IIIB T4 N3 . In T4 category , patient pleural pericardial effusion multiple nodule lobe exclude . Patients T4 disease secondary extensive massive involvement great vessel excluded.Patients exclude expect risk pulmonary toxicity likely high , e.g . V20 excess 35 % . 4 . Males female age 18 75 year . 5 . Life expectancy least 12 week . 6. WHO performance status 0 1 . 7 . Weight loss &lt; =10 % within last 3 month . 8 . Laboratory requirement entry ( within 7 day randomization ) : Blood cell count : Absolute neutrophils &gt; = 2.0 x 10^9/L Platelets &gt; = 100 x 10^9/L Hemoglobin &gt; = 10 g/dl Renal function : Serum creatinine &lt; =1 x upper limit normal ( UNL ) . In case borderline value serum creatinine , 24h creatinine clearance &gt; = 60 mL/min . Hepatic function : Serum bilirubin &lt; = 1 x UNL ASAT ALAT &lt; = 2.5 x UNL Alkaline phosphatase &lt; = 5 x UNL Patients ASAT and/or ALAT &gt; 1.5 x UNL associate alkaline phosphatase &gt; 2.5 x UNL eligible study . 9 . Lung function test entry : FEV1 : &gt; = 50 % x Normal value DLCO : &gt; = 50 % x Normal value 10 . Adequate cardiac function . 11 . Patient either measurable and/or nonmeasurable lesion ( accord RECIST criterion ) . 1 . Diagnosis small cell lung cancer . 2 . Pregnant lactating woman . 3 . Patients ( male female ) reproductive potential implementing adequate contraceptive measure . 4 . Prior systemic chemotherapy , immunotherapy , biological therapy include neoadjuvant adjuvant treatment NSCLC . 5 . Prior surgery NSCLC , less 5 year study . 6 . Prior radiotherapy NSCLC . 7 . History prior malignancy , except cure nonmelanoma skin cancer , curatively treat insitu carcinoma cervix cancer curatively treat evidence disease least five year . 8 . Symptomatic peripheral neuropathy Grade &gt; = 2 except due trauma . 9 . Other serious concomitant illness medical condition : Congestive heart failure angina pectoris except medically control . Previous history myocardial infarction within 1 year study entry , uncontrolled hypertension arrhythmia . History significant neurological psychiatric disorder include dementia seizure . Active infection require IV antibiotic . Active ulcer , unstable diabetes mellitus contraindication corticosteroid therapy . Superior vena cava syndrome contraindicate hydration . Preexisting pericardial effusion . Preexisting symptomatic pleural effusion . 10 . Significant gastrointestinal abnormality , include requirement intravenous nutrition , active peptic ulcer disease , prior surgical procedure affect absorption . 11 . Distant metastasis . 12 . Concurrent treatment experimental anticancer drug . 13 . Concomitant within 4week period administration experimental drug investigation . 14 . Significant ophthalmologic abnormality . 15 . Moderate severe dermatitis . 16 . Hypersensitivity docetaxel , cisplatin , excipients . 17 . Concomitant use phenytoin , carbamazepin , barbiturate , rifampicin . 18 . Mental condition render patient unable understand nature , scope , possible consequence study . 19 . Patient unlikely comply protocol , i.e. , uncooperative attitude , inability return followup visit , likely complete study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>